News - NObreath FeNO Device by Bedfont Scientific Ltd.

Oct 29

Bedfont® Scientific strengthens its commitment to respiratory clinical research

Bedfont® now focuses on supporting clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH in Basel. Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of experience manufacturing medical devices, has quietly supported respiratory research around the world and is set to make its... read more →

Oct 28

What does good asthma control really look like?

Asthma is a chronic lung condition affecting approximately 339.4 million people worldwide1, and when uncontrolled, it can be quite debilitating in everyday life. Despite modern-day medicine and the availability of effective treatments, approximately 39% of people with asthma remain uncontrolled1. What do we mean by asthma control? Asthma can cause... read more →

Aug 11

Bedfont® brings respiratory monitoring solutions to ERS with a focus on clinical research

Showcasing the NObreath® and Smokerlyzer® range while connecting with research teams and global distribution partners at Europe's leading respiratory congress. Bedfont® Scientific Limited, a world leader in breath analysis, is excited to be attending this year's European Respiratory Society (ERS) Congress in Barcelona. With over 50 years of experience in... read more →

Jul 06

Asthma care is evolving. How FeNO testing is changing the way we treat asthma

Over 1,200 NObreath® FeNO devices sold since the 2024 UK guideline update. Bedfont® Scientific Limited, an innovative leader in breath analysis and Fractional exhaled Nitric Oxide (FeNO) testing for asthma care with the NObreath®, welcomes the news that over 1 million people with asthma are now using combination inhalers1 following... read more →

Jul 06

Love Your Lungs week 2026

Written by Carol Stonham MBE This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the NObreath® is as follows: The 2nd generation NObreath® is a breath nitric oxide (NO) test system intended to measure fractional exhaled nitric oxide (FeNO) in... read more →

May 29

Beyond symptom relief: What the 1 million inhaler milestone reveals about modern asthma care

Almost 10 months after the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) released an updated joint guideline for asthma care and management, a major milestone has been hit. Over 1 million people are now using combination... read more →

May 18

Bedfont® Scientific targets international growth at EAACI Congress 2026

Demonstrating innovations in respiratory and allergy diagnostics with the NObreath® and Gastrolyzer® range. Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI)... read more →

Apr 30

Shaping the future of asthma management with the NObreath® at ATS 2026

Bedfont® Scientific Limited to showcase why the NObreath® is the FeNO device of choice at this year’s global event. World leaders in breath analysis Bedfont® Scientific Ltd. are pleased to be attending this years American Thoracic Society (ATS) International Conference, to exhibit the innovative NObreath® Fractional exhaled Nitric Oxide (FeNO)... read more →

Apr 21

Advancements in FeNO testing for better asthma control

In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but this is sadly not always the case. Airway inflammation is... read more →

Apr 08

Turning awareness into action: Expanding access to better asthma care this Asthma and Allergy Awareness Month

Over 28 million people in the United States (US) have asthma1,2, with the condition named as the leading chronic disease in children, affecting approximately 4.9 million under the age of 182,3. In the US, asthma is one of the most common and costly diseases, and these stark figures highlight why asthma... read more →